Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 73,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'catslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 73,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [
			[maximum depth reached]
		]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/patients039-groups-voice-patent-fears-4675150/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/patients039-groups-voice-patent-fears-4675150/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'catslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 73
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 74,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'artileslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 74,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [
			[maximum depth reached]
		]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/patients039-groups-voice-patent-fears-4675150/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/patients039-groups-voice-patent-fears-4675150/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'artileslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 74
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Warning (512): Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853 [CORE/src/Http/ResponseEmitter.php, line 48]
Code Context
            if (Configure::read('debug')) {

                trigger_error($message, E_USER_WARNING);

            } else {
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr6803085150bda-trace').style.display = (document.getElementById('cakeErr6803085150bda-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr6803085150bda-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr6803085150bda-code').style.display = (document.getElementById('cakeErr6803085150bda-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr6803085150bda-context').style.display = (document.getElementById('cakeErr6803085150bda-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr6803085150bda-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr6803085150bda-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 27103,
		&#039;title&#039; =&gt; &#039;Patients&amp;#039; groups voice patent fears&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Telegraph
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;em&gt;New Delhi: &lt;/em&gt;Health and patients&#039; rights groups have called on the government to resist American pressure that they claimed was aimed at weakening safeguards in India&#039;s patent laws that allow drug companies to sell inexpensive generic medicine.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Health activists representing patients&#039; rights said they were concerned that bilateral talks on intellectual property rights, to feature during US President Barack Obama&#039;s visit to India beginning this weekend, may be rigged against access to affordable medicine for patients in India and other countries.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
They said their concerns were based on a series of developments since Prime Minister Narendra Modi&#039;s return from a visit to the US in September 2014 that, they claimed, suggested that the US was accelerating its efforts to weaken or bypass India&#039;s pro-poor patent laws.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
India&#039;s patent laws contain a section titled 3(d) that prohibits patents on minor variations of known drug molecules. Patients&#039; rights groups view this as a safeguard, facilitating the production of generic inexpensive versions of medicines sold in India and many other countries.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Indian patent examiners have denied patents citing 3(d), which sections of foreign pharmaceutical industry see as a hindrance to innovation.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;(Narendra) Modi has portrayed himself as a strong man - we&#039;re calling on Modi to show his strength now and resist pressure from the US,&amp;quot; said Anand Grover, director of Lawyers Collective, a network of lawyers that has represented patients&#039; groups to challenge patent decisions in court.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Grover and others view bilateral mechanisms set up through the US-India Trade Policy Forum and an investigation into Indian patent laws initiated by the US International Trade Commission in October 2014 as signals of the growing US pressure on India to tweak the way it manages patents.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
They said certain actions by the Indian government also suggested that it was willing to rethink India&#039;s patent regime. The government last year established a think-tank on intellectual property rights (IPR) and decided to defer a decision to allow generic production of an anti-cancer drug.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;We welcome President Obama as a representative of the US people, but we don&#039;t want him here as a representative of US pharmaceutical companies,&amp;quot; said Amit Sengupta, a physician who is the convener of Jan Swasthya Abhiyan, or People&#039;s Health Network, a non-government group of health activists.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Grover said the draft national policy on intellectual property released by the government&#039;s new think-tank is &amp;quot;glaringly ignorant and promotes intellectual property as the only solution for innovation and creativity in India, contrary to the evidence&amp;quot;.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
International humanitarian groups are also concerned that weakened IPR policies in India would hurt patients in developing countries. &amp;quot;India has earned itself the title of the pharmacy of the world through its inexpensive generic drugs,&amp;quot; said Leena Menghaney, an India representative with Medicins Sans Frontieres that procures drugs against malaria, tuberculosis, and HIV from India for patients in other developing countries.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;What we&#039;re witnessing now are intense efforts to find ways to weaken or bypass the patent law that was passed by the Indian Parliament - unanimously by members of all political parties,&amp;quot; said Dinesh Abrol, the convener of the National Working Group on Patent Laws.
&lt;/p&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Telegraph, 24 January, 2015, http://www.telegraphindia.com/1150124/jsp/nation/story_9985.jsp#.VMNmUC7xyBE&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;patients039-groups-voice-patent-fears-4675150&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 4675150,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 27103,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Patients&amp;#039; groups voice patent fears&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;Access to Health,Access to Healthcare,Access to Medicines,Intellectual Property Rights,patent,patents,IPRs,medicines&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Telegraph


New Delhi: Health and patients&#039; rights groups have called on the government to resist American pressure that they claimed was aimed at weakening safeguards in India&#039;s patent laws that allow drug companies to sell inexpensive generic medicine.


Health activists representing...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Telegraph&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;em&gt;New Delhi: &lt;/em&gt;Health and patients&#039; rights groups have called on the government to resist American pressure that they claimed was aimed at weakening safeguards in India&#039;s patent laws that allow drug companies to sell inexpensive generic medicine.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Health activists representing patients&#039; rights said they were concerned that bilateral talks on intellectual property rights, to feature during US President Barack Obama&#039;s visit to India beginning this weekend, may be rigged against access to affordable medicine for patients in India and other countries.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;They said their concerns were based on a series of developments since Prime Minister Narendra Modi&#039;s return from a visit to the US in September 2014 that, they claimed, suggested that the US was accelerating its efforts to weaken or bypass India&#039;s pro-poor patent laws.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;India&#039;s patent laws contain a section titled 3(d) that prohibits patents on minor variations of known drug molecules. Patients&#039; rights groups view this as a safeguard, facilitating the production of generic inexpensive versions of medicines sold in India and many other countries.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Indian patent examiners have denied patents citing 3(d), which sections of foreign pharmaceutical industry see as a hindrance to innovation.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;(Narendra) Modi has portrayed himself as a strong man - we&#039;re calling on Modi to show his strength now and resist pressure from the US,&amp;quot; said Anand Grover, director of Lawyers Collective, a network of lawyers that has represented patients&#039; groups to challenge patent decisions in court.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Grover and others view bilateral mechanisms set up through the US-India Trade Policy Forum and an investigation into Indian patent laws initiated by the US International Trade Commission in October 2014 as signals of the growing US pressure on India to tweak the way it manages patents.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;They said certain actions by the Indian government also suggested that it was willing to rethink India&#039;s patent regime. The government last year established a think-tank on intellectual property rights (IPR) and decided to defer a decision to allow generic production of an anti-cancer drug.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;We welcome President Obama as a representative of the US people, but we don&#039;t want him here as a representative of US pharmaceutical companies,&amp;quot; said Amit Sengupta, a physician who is the convener of Jan Swasthya Abhiyan, or People&#039;s Health Network, a non-government group of health activists.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Grover said the draft national policy on intellectual property released by the government&#039;s new think-tank is &amp;quot;glaringly ignorant and promotes intellectual property as the only solution for innovation and creativity in India, contrary to the evidence&amp;quot;.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;International humanitarian groups are also concerned that weakened IPR policies in India would hurt patients in developing countries. &amp;quot;India has earned itself the title of the pharmacy of the world through its inexpensive generic drugs,&amp;quot; said Leena Menghaney, an India representative with Medicins Sans Frontieres that procures drugs against malaria, tuberculosis, and HIV from India for patients in other developing countries.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;What we&#039;re witnessing now are intense efforts to find ways to weaken or bypass the patent law that was passed by the Indian Parliament - unanimously by members of all political parties,&amp;quot; said Dinesh Abrol, the convener of the National Working Group on Patent Laws.&lt;/p&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 27103,
	&#039;title&#039; =&gt; &#039;Patients&amp;#039; groups voice patent fears&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Telegraph
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;em&gt;New Delhi: &lt;/em&gt;Health and patients&#039; rights groups have called on the government to resist American pressure that they claimed was aimed at weakening safeguards in India&#039;s patent laws that allow drug companies to sell inexpensive generic medicine.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Health activists representing patients&#039; rights said they were concerned that bilateral talks on intellectual property rights, to feature during US President Barack Obama&#039;s visit to India beginning this weekend, may be rigged against access to affordable medicine for patients in India and other countries.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
They said their concerns were based on a series of developments since Prime Minister Narendra Modi&#039;s return from a visit to the US in September 2014 that, they claimed, suggested that the US was accelerating its efforts to weaken or bypass India&#039;s pro-poor patent laws.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
India&#039;s patent laws contain a section titled 3(d) that prohibits patents on minor variations of known drug molecules. Patients&#039; rights groups view this as a safeguard, facilitating the production of generic inexpensive versions of medicines sold in India and many other countries.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Indian patent examiners have denied patents citing 3(d), which sections of foreign pharmaceutical industry see as a hindrance to innovation.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;(Narendra) Modi has portrayed himself as a strong man - we&#039;re calling on Modi to show his strength now and resist pressure from the US,&amp;quot; said Anand Grover, director of Lawyers Collective, a network of lawyers that has represented patients&#039; groups to challenge patent decisions in court.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Grover and others view bilateral mechanisms set up through the US-India Trade Policy Forum and an investigation into Indian patent laws initiated by the US International Trade Commission in October 2014 as signals of the growing US pressure on India to tweak the way it manages patents.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
They said certain actions by the Indian government also suggested that it was willing to rethink India&#039;s patent regime. The government last year established a think-tank on intellectual property rights (IPR) and decided to defer a decision to allow generic production of an anti-cancer drug.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;We welcome President Obama as a representative of the US people, but we don&#039;t want him here as a representative of US pharmaceutical companies,&amp;quot; said Amit Sengupta, a physician who is the convener of Jan Swasthya Abhiyan, or People&#039;s Health Network, a non-government group of health activists.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Grover said the draft national policy on intellectual property released by the government&#039;s new think-tank is &amp;quot;glaringly ignorant and promotes intellectual property as the only solution for innovation and creativity in India, contrary to the evidence&amp;quot;.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
International humanitarian groups are also concerned that weakened IPR policies in India would hurt patients in developing countries. &amp;quot;India has earned itself the title of the pharmacy of the world through its inexpensive generic drugs,&amp;quot; said Leena Menghaney, an India representative with Medicins Sans Frontieres that procures drugs against malaria, tuberculosis, and HIV from India for patients in other developing countries.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;What we&#039;re witnessing now are intense efforts to find ways to weaken or bypass the patent law that was passed by the Indian Parliament - unanimously by members of all political parties,&amp;quot; said Dinesh Abrol, the convener of the National Working Group on Patent Laws.
&lt;/p&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Telegraph, 24 January, 2015, http://www.telegraphindia.com/1150124/jsp/nation/story_9985.jsp#.VMNmUC7xyBE&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;patients039-groups-voice-patent-fears-4675150&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 4675150,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {},
		(int) 3 =&gt; object(Cake\ORM\Entity) {},
		(int) 4 =&gt; object(Cake\ORM\Entity) {},
		(int) 5 =&gt; object(Cake\ORM\Entity) {},
		(int) 6 =&gt; object(Cake\ORM\Entity) {},
		(int) 7 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 27103
$metaTitle = &#039;LATEST NEWS UPDATES | Patients&amp;#039; groups voice patent fears&#039;
$metaKeywords = &#039;Access to Health,Access to Healthcare,Access to Medicines,Intellectual Property Rights,patent,patents,IPRs,medicines&#039;
$metaDesc = &#039;
-The Telegraph


New Delhi: Health and patients&#039; rights groups have called on the government to resist American pressure that they claimed was aimed at weakening safeguards in India&#039;s patent laws that allow drug companies to sell inexpensive generic medicine.


Health activists representing...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Telegraph&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;em&gt;New Delhi: &lt;/em&gt;Health and patients&#039; rights groups have called on the government to resist American pressure that they claimed was aimed at weakening safeguards in India&#039;s patent laws that allow drug companies to sell inexpensive generic medicine.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Health activists representing patients&#039; rights said they were concerned that bilateral talks on intellectual property rights, to feature during US President Barack Obama&#039;s visit to India beginning this weekend, may be rigged against access to affordable medicine for patients in India and other countries.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;They said their concerns were based on a series of developments since Prime Minister Narendra Modi&#039;s return from a visit to the US in September 2014 that, they claimed, suggested that the US was accelerating its efforts to weaken or bypass India&#039;s pro-poor patent laws.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;India&#039;s patent laws contain a section titled 3(d) that prohibits patents on minor variations of known drug molecules. Patients&#039; rights groups view this as a safeguard, facilitating the production of generic inexpensive versions of medicines sold in India and many other countries.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Indian patent examiners have denied patents citing 3(d), which sections of foreign pharmaceutical industry see as a hindrance to innovation.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;(Narendra) Modi has portrayed himself as a strong man - we&#039;re calling on Modi to show his strength now and resist pressure from the US,&amp;quot; said Anand Grover, director of Lawyers Collective, a network of lawyers that has represented patients&#039; groups to challenge patent decisions in court.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Grover and others view bilateral mechanisms set up through the US-India Trade Policy Forum and an investigation into Indian patent laws initiated by the US International Trade Commission in October 2014 as signals of the growing US pressure on India to tweak the way it manages patents.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;They said certain actions by the Indian government also suggested that it was willing to rethink India&#039;s patent regime. The government last year established a think-tank on intellectual property rights (IPR) and decided to defer a decision to allow generic production of an anti-cancer drug.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;We welcome President Obama as a representative of the US people, but we don&#039;t want him here as a representative of US pharmaceutical companies,&amp;quot; said Amit Sengupta, a physician who is the convener of Jan Swasthya Abhiyan, or People&#039;s Health Network, a non-government group of health activists.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Grover said the draft national policy on intellectual property released by the government&#039;s new think-tank is &amp;quot;glaringly ignorant and promotes intellectual property as the only solution for innovation and creativity in India, contrary to the evidence&amp;quot;.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;International humanitarian groups are also concerned that weakened IPR policies in India would hurt patients in developing countries. &amp;quot;India has earned itself the title of the pharmacy of the world through its inexpensive generic drugs,&amp;quot; said Leena Menghaney, an India representative with Medicins Sans Frontieres that procures drugs against malaria, tuberculosis, and HIV from India for patients in other developing countries.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;What we&#039;re witnessing now are intense efforts to find ways to weaken or bypass the patent law that was passed by the Indian Parliament - unanimously by members of all political parties,&amp;quot; said Dinesh Abrol, the convener of the National Working Group on Patent Laws.&lt;/p&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/patients039-groups-voice-patent-fears-4675150.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Patients&#039; groups voice patent fears | Im4change.org</title>
    <meta name="description" content="
-The Telegraph


New Delhi: Health and patients' rights groups have called on the government to resist American pressure that they claimed was aimed at weakening safeguards in India's patent laws that allow drug companies to sell inexpensive generic medicine.


Health activists representing..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Patients&#039; groups voice patent fears</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Telegraph</div><p align="justify"><em>New Delhi: </em>Health and patients' rights groups have called on the government to resist American pressure that they claimed was aimed at weakening safeguards in India's patent laws that allow drug companies to sell inexpensive generic medicine.</p><p align="justify">Health activists representing patients' rights said they were concerned that bilateral talks on intellectual property rights, to feature during US President Barack Obama's visit to India beginning this weekend, may be rigged against access to affordable medicine for patients in India and other countries.</p><p align="justify">They said their concerns were based on a series of developments since Prime Minister Narendra Modi's return from a visit to the US in September 2014 that, they claimed, suggested that the US was accelerating its efforts to weaken or bypass India's pro-poor patent laws.</p><p align="justify">India's patent laws contain a section titled 3(d) that prohibits patents on minor variations of known drug molecules. Patients' rights groups view this as a safeguard, facilitating the production of generic inexpensive versions of medicines sold in India and many other countries.</p><p align="justify">Indian patent examiners have denied patents citing 3(d), which sections of foreign pharmaceutical industry see as a hindrance to innovation.</p><p align="justify">&quot;(Narendra) Modi has portrayed himself as a strong man - we're calling on Modi to show his strength now and resist pressure from the US,&quot; said Anand Grover, director of Lawyers Collective, a network of lawyers that has represented patients' groups to challenge patent decisions in court.</p><p align="justify">Grover and others view bilateral mechanisms set up through the US-India Trade Policy Forum and an investigation into Indian patent laws initiated by the US International Trade Commission in October 2014 as signals of the growing US pressure on India to tweak the way it manages patents.</p><p align="justify">They said certain actions by the Indian government also suggested that it was willing to rethink India's patent regime. The government last year established a think-tank on intellectual property rights (IPR) and decided to defer a decision to allow generic production of an anti-cancer drug.</p><p align="justify">&quot;We welcome President Obama as a representative of the US people, but we don't want him here as a representative of US pharmaceutical companies,&quot; said Amit Sengupta, a physician who is the convener of Jan Swasthya Abhiyan, or People's Health Network, a non-government group of health activists.</p><p align="justify">Grover said the draft national policy on intellectual property released by the government's new think-tank is &quot;glaringly ignorant and promotes intellectual property as the only solution for innovation and creativity in India, contrary to the evidence&quot;.</p><p align="justify">International humanitarian groups are also concerned that weakened IPR policies in India would hurt patients in developing countries. &quot;India has earned itself the title of the pharmacy of the world through its inexpensive generic drugs,&quot; said Leena Menghaney, an India representative with Medicins Sans Frontieres that procures drugs against malaria, tuberculosis, and HIV from India for patients in other developing countries.</p><p align="justify">&quot;What we're witnessing now are intense efforts to find ways to weaken or bypass the patent law that was passed by the Indian Parliament - unanimously by members of all political parties,&quot; said Dinesh Abrol, the convener of the National Working Group on Patent Laws.</p>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$maxBufferLength = (int) 8192
$file = '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php'
$line = (int) 853
$message = 'Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853'
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 48
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 148]
Code Context
            $response->getStatusCode(),

            ($reasonPhrase ? ' ' . $reasonPhrase : '')

        ));
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr6803085150bda-trace').style.display = (document.getElementById('cakeErr6803085150bda-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr6803085150bda-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr6803085150bda-code').style.display = (document.getElementById('cakeErr6803085150bda-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr6803085150bda-context').style.display = (document.getElementById('cakeErr6803085150bda-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr6803085150bda-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr6803085150bda-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 27103,
		&#039;title&#039; =&gt; &#039;Patients&amp;#039; groups voice patent fears&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Telegraph
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;em&gt;New Delhi: &lt;/em&gt;Health and patients&#039; rights groups have called on the government to resist American pressure that they claimed was aimed at weakening safeguards in India&#039;s patent laws that allow drug companies to sell inexpensive generic medicine.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Health activists representing patients&#039; rights said they were concerned that bilateral talks on intellectual property rights, to feature during US President Barack Obama&#039;s visit to India beginning this weekend, may be rigged against access to affordable medicine for patients in India and other countries.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
They said their concerns were based on a series of developments since Prime Minister Narendra Modi&#039;s return from a visit to the US in September 2014 that, they claimed, suggested that the US was accelerating its efforts to weaken or bypass India&#039;s pro-poor patent laws.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
India&#039;s patent laws contain a section titled 3(d) that prohibits patents on minor variations of known drug molecules. Patients&#039; rights groups view this as a safeguard, facilitating the production of generic inexpensive versions of medicines sold in India and many other countries.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Indian patent examiners have denied patents citing 3(d), which sections of foreign pharmaceutical industry see as a hindrance to innovation.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;(Narendra) Modi has portrayed himself as a strong man - we&#039;re calling on Modi to show his strength now and resist pressure from the US,&amp;quot; said Anand Grover, director of Lawyers Collective, a network of lawyers that has represented patients&#039; groups to challenge patent decisions in court.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Grover and others view bilateral mechanisms set up through the US-India Trade Policy Forum and an investigation into Indian patent laws initiated by the US International Trade Commission in October 2014 as signals of the growing US pressure on India to tweak the way it manages patents.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
They said certain actions by the Indian government also suggested that it was willing to rethink India&#039;s patent regime. The government last year established a think-tank on intellectual property rights (IPR) and decided to defer a decision to allow generic production of an anti-cancer drug.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;We welcome President Obama as a representative of the US people, but we don&#039;t want him here as a representative of US pharmaceutical companies,&amp;quot; said Amit Sengupta, a physician who is the convener of Jan Swasthya Abhiyan, or People&#039;s Health Network, a non-government group of health activists.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Grover said the draft national policy on intellectual property released by the government&#039;s new think-tank is &amp;quot;glaringly ignorant and promotes intellectual property as the only solution for innovation and creativity in India, contrary to the evidence&amp;quot;.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
International humanitarian groups are also concerned that weakened IPR policies in India would hurt patients in developing countries. &amp;quot;India has earned itself the title of the pharmacy of the world through its inexpensive generic drugs,&amp;quot; said Leena Menghaney, an India representative with Medicins Sans Frontieres that procures drugs against malaria, tuberculosis, and HIV from India for patients in other developing countries.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;What we&#039;re witnessing now are intense efforts to find ways to weaken or bypass the patent law that was passed by the Indian Parliament - unanimously by members of all political parties,&amp;quot; said Dinesh Abrol, the convener of the National Working Group on Patent Laws.
&lt;/p&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Telegraph, 24 January, 2015, http://www.telegraphindia.com/1150124/jsp/nation/story_9985.jsp#.VMNmUC7xyBE&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;patients039-groups-voice-patent-fears-4675150&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 4675150,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 27103,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Patients&amp;#039; groups voice patent fears&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;Access to Health,Access to Healthcare,Access to Medicines,Intellectual Property Rights,patent,patents,IPRs,medicines&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Telegraph


New Delhi: Health and patients&#039; rights groups have called on the government to resist American pressure that they claimed was aimed at weakening safeguards in India&#039;s patent laws that allow drug companies to sell inexpensive generic medicine.


Health activists representing...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Telegraph&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;em&gt;New Delhi: &lt;/em&gt;Health and patients&#039; rights groups have called on the government to resist American pressure that they claimed was aimed at weakening safeguards in India&#039;s patent laws that allow drug companies to sell inexpensive generic medicine.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Health activists representing patients&#039; rights said they were concerned that bilateral talks on intellectual property rights, to feature during US President Barack Obama&#039;s visit to India beginning this weekend, may be rigged against access to affordable medicine for patients in India and other countries.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;They said their concerns were based on a series of developments since Prime Minister Narendra Modi&#039;s return from a visit to the US in September 2014 that, they claimed, suggested that the US was accelerating its efforts to weaken or bypass India&#039;s pro-poor patent laws.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;India&#039;s patent laws contain a section titled 3(d) that prohibits patents on minor variations of known drug molecules. Patients&#039; rights groups view this as a safeguard, facilitating the production of generic inexpensive versions of medicines sold in India and many other countries.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Indian patent examiners have denied patents citing 3(d), which sections of foreign pharmaceutical industry see as a hindrance to innovation.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;(Narendra) Modi has portrayed himself as a strong man - we&#039;re calling on Modi to show his strength now and resist pressure from the US,&amp;quot; said Anand Grover, director of Lawyers Collective, a network of lawyers that has represented patients&#039; groups to challenge patent decisions in court.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Grover and others view bilateral mechanisms set up through the US-India Trade Policy Forum and an investigation into Indian patent laws initiated by the US International Trade Commission in October 2014 as signals of the growing US pressure on India to tweak the way it manages patents.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;They said certain actions by the Indian government also suggested that it was willing to rethink India&#039;s patent regime. The government last year established a think-tank on intellectual property rights (IPR) and decided to defer a decision to allow generic production of an anti-cancer drug.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;We welcome President Obama as a representative of the US people, but we don&#039;t want him here as a representative of US pharmaceutical companies,&amp;quot; said Amit Sengupta, a physician who is the convener of Jan Swasthya Abhiyan, or People&#039;s Health Network, a non-government group of health activists.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Grover said the draft national policy on intellectual property released by the government&#039;s new think-tank is &amp;quot;glaringly ignorant and promotes intellectual property as the only solution for innovation and creativity in India, contrary to the evidence&amp;quot;.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;International humanitarian groups are also concerned that weakened IPR policies in India would hurt patients in developing countries. &amp;quot;India has earned itself the title of the pharmacy of the world through its inexpensive generic drugs,&amp;quot; said Leena Menghaney, an India representative with Medicins Sans Frontieres that procures drugs against malaria, tuberculosis, and HIV from India for patients in other developing countries.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;What we&#039;re witnessing now are intense efforts to find ways to weaken or bypass the patent law that was passed by the Indian Parliament - unanimously by members of all political parties,&amp;quot; said Dinesh Abrol, the convener of the National Working Group on Patent Laws.&lt;/p&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 27103,
	&#039;title&#039; =&gt; &#039;Patients&amp;#039; groups voice patent fears&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Telegraph
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;em&gt;New Delhi: &lt;/em&gt;Health and patients&#039; rights groups have called on the government to resist American pressure that they claimed was aimed at weakening safeguards in India&#039;s patent laws that allow drug companies to sell inexpensive generic medicine.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Health activists representing patients&#039; rights said they were concerned that bilateral talks on intellectual property rights, to feature during US President Barack Obama&#039;s visit to India beginning this weekend, may be rigged against access to affordable medicine for patients in India and other countries.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
They said their concerns were based on a series of developments since Prime Minister Narendra Modi&#039;s return from a visit to the US in September 2014 that, they claimed, suggested that the US was accelerating its efforts to weaken or bypass India&#039;s pro-poor patent laws.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
India&#039;s patent laws contain a section titled 3(d) that prohibits patents on minor variations of known drug molecules. Patients&#039; rights groups view this as a safeguard, facilitating the production of generic inexpensive versions of medicines sold in India and many other countries.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Indian patent examiners have denied patents citing 3(d), which sections of foreign pharmaceutical industry see as a hindrance to innovation.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;(Narendra) Modi has portrayed himself as a strong man - we&#039;re calling on Modi to show his strength now and resist pressure from the US,&amp;quot; said Anand Grover, director of Lawyers Collective, a network of lawyers that has represented patients&#039; groups to challenge patent decisions in court.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Grover and others view bilateral mechanisms set up through the US-India Trade Policy Forum and an investigation into Indian patent laws initiated by the US International Trade Commission in October 2014 as signals of the growing US pressure on India to tweak the way it manages patents.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
They said certain actions by the Indian government also suggested that it was willing to rethink India&#039;s patent regime. The government last year established a think-tank on intellectual property rights (IPR) and decided to defer a decision to allow generic production of an anti-cancer drug.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;We welcome President Obama as a representative of the US people, but we don&#039;t want him here as a representative of US pharmaceutical companies,&amp;quot; said Amit Sengupta, a physician who is the convener of Jan Swasthya Abhiyan, or People&#039;s Health Network, a non-government group of health activists.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Grover said the draft national policy on intellectual property released by the government&#039;s new think-tank is &amp;quot;glaringly ignorant and promotes intellectual property as the only solution for innovation and creativity in India, contrary to the evidence&amp;quot;.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
International humanitarian groups are also concerned that weakened IPR policies in India would hurt patients in developing countries. &amp;quot;India has earned itself the title of the pharmacy of the world through its inexpensive generic drugs,&amp;quot; said Leena Menghaney, an India representative with Medicins Sans Frontieres that procures drugs against malaria, tuberculosis, and HIV from India for patients in other developing countries.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;What we&#039;re witnessing now are intense efforts to find ways to weaken or bypass the patent law that was passed by the Indian Parliament - unanimously by members of all political parties,&amp;quot; said Dinesh Abrol, the convener of the National Working Group on Patent Laws.
&lt;/p&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Telegraph, 24 January, 2015, http://www.telegraphindia.com/1150124/jsp/nation/story_9985.jsp#.VMNmUC7xyBE&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;patients039-groups-voice-patent-fears-4675150&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 4675150,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {},
		(int) 3 =&gt; object(Cake\ORM\Entity) {},
		(int) 4 =&gt; object(Cake\ORM\Entity) {},
		(int) 5 =&gt; object(Cake\ORM\Entity) {},
		(int) 6 =&gt; object(Cake\ORM\Entity) {},
		(int) 7 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 27103
$metaTitle = &#039;LATEST NEWS UPDATES | Patients&amp;#039; groups voice patent fears&#039;
$metaKeywords = &#039;Access to Health,Access to Healthcare,Access to Medicines,Intellectual Property Rights,patent,patents,IPRs,medicines&#039;
$metaDesc = &#039;
-The Telegraph


New Delhi: Health and patients&#039; rights groups have called on the government to resist American pressure that they claimed was aimed at weakening safeguards in India&#039;s patent laws that allow drug companies to sell inexpensive generic medicine.


Health activists representing...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Telegraph&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;em&gt;New Delhi: &lt;/em&gt;Health and patients&#039; rights groups have called on the government to resist American pressure that they claimed was aimed at weakening safeguards in India&#039;s patent laws that allow drug companies to sell inexpensive generic medicine.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Health activists representing patients&#039; rights said they were concerned that bilateral talks on intellectual property rights, to feature during US President Barack Obama&#039;s visit to India beginning this weekend, may be rigged against access to affordable medicine for patients in India and other countries.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;They said their concerns were based on a series of developments since Prime Minister Narendra Modi&#039;s return from a visit to the US in September 2014 that, they claimed, suggested that the US was accelerating its efforts to weaken or bypass India&#039;s pro-poor patent laws.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;India&#039;s patent laws contain a section titled 3(d) that prohibits patents on minor variations of known drug molecules. Patients&#039; rights groups view this as a safeguard, facilitating the production of generic inexpensive versions of medicines sold in India and many other countries.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Indian patent examiners have denied patents citing 3(d), which sections of foreign pharmaceutical industry see as a hindrance to innovation.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;(Narendra) Modi has portrayed himself as a strong man - we&#039;re calling on Modi to show his strength now and resist pressure from the US,&amp;quot; said Anand Grover, director of Lawyers Collective, a network of lawyers that has represented patients&#039; groups to challenge patent decisions in court.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Grover and others view bilateral mechanisms set up through the US-India Trade Policy Forum and an investigation into Indian patent laws initiated by the US International Trade Commission in October 2014 as signals of the growing US pressure on India to tweak the way it manages patents.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;They said certain actions by the Indian government also suggested that it was willing to rethink India&#039;s patent regime. The government last year established a think-tank on intellectual property rights (IPR) and decided to defer a decision to allow generic production of an anti-cancer drug.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;We welcome President Obama as a representative of the US people, but we don&#039;t want him here as a representative of US pharmaceutical companies,&amp;quot; said Amit Sengupta, a physician who is the convener of Jan Swasthya Abhiyan, or People&#039;s Health Network, a non-government group of health activists.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Grover said the draft national policy on intellectual property released by the government&#039;s new think-tank is &amp;quot;glaringly ignorant and promotes intellectual property as the only solution for innovation and creativity in India, contrary to the evidence&amp;quot;.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;International humanitarian groups are also concerned that weakened IPR policies in India would hurt patients in developing countries. &amp;quot;India has earned itself the title of the pharmacy of the world through its inexpensive generic drugs,&amp;quot; said Leena Menghaney, an India representative with Medicins Sans Frontieres that procures drugs against malaria, tuberculosis, and HIV from India for patients in other developing countries.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;What we&#039;re witnessing now are intense efforts to find ways to weaken or bypass the patent law that was passed by the Indian Parliament - unanimously by members of all political parties,&amp;quot; said Dinesh Abrol, the convener of the National Working Group on Patent Laws.&lt;/p&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/patients039-groups-voice-patent-fears-4675150.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Patients&#039; groups voice patent fears | Im4change.org</title>
    <meta name="description" content="
-The Telegraph


New Delhi: Health and patients' rights groups have called on the government to resist American pressure that they claimed was aimed at weakening safeguards in India's patent laws that allow drug companies to sell inexpensive generic medicine.


Health activists representing..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Patients&#039; groups voice patent fears</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Telegraph</div><p align="justify"><em>New Delhi: </em>Health and patients' rights groups have called on the government to resist American pressure that they claimed was aimed at weakening safeguards in India's patent laws that allow drug companies to sell inexpensive generic medicine.</p><p align="justify">Health activists representing patients' rights said they were concerned that bilateral talks on intellectual property rights, to feature during US President Barack Obama's visit to India beginning this weekend, may be rigged against access to affordable medicine for patients in India and other countries.</p><p align="justify">They said their concerns were based on a series of developments since Prime Minister Narendra Modi's return from a visit to the US in September 2014 that, they claimed, suggested that the US was accelerating its efforts to weaken or bypass India's pro-poor patent laws.</p><p align="justify">India's patent laws contain a section titled 3(d) that prohibits patents on minor variations of known drug molecules. Patients' rights groups view this as a safeguard, facilitating the production of generic inexpensive versions of medicines sold in India and many other countries.</p><p align="justify">Indian patent examiners have denied patents citing 3(d), which sections of foreign pharmaceutical industry see as a hindrance to innovation.</p><p align="justify">&quot;(Narendra) Modi has portrayed himself as a strong man - we're calling on Modi to show his strength now and resist pressure from the US,&quot; said Anand Grover, director of Lawyers Collective, a network of lawyers that has represented patients' groups to challenge patent decisions in court.</p><p align="justify">Grover and others view bilateral mechanisms set up through the US-India Trade Policy Forum and an investigation into Indian patent laws initiated by the US International Trade Commission in October 2014 as signals of the growing US pressure on India to tweak the way it manages patents.</p><p align="justify">They said certain actions by the Indian government also suggested that it was willing to rethink India's patent regime. The government last year established a think-tank on intellectual property rights (IPR) and decided to defer a decision to allow generic production of an anti-cancer drug.</p><p align="justify">&quot;We welcome President Obama as a representative of the US people, but we don't want him here as a representative of US pharmaceutical companies,&quot; said Amit Sengupta, a physician who is the convener of Jan Swasthya Abhiyan, or People's Health Network, a non-government group of health activists.</p><p align="justify">Grover said the draft national policy on intellectual property released by the government's new think-tank is &quot;glaringly ignorant and promotes intellectual property as the only solution for innovation and creativity in India, contrary to the evidence&quot;.</p><p align="justify">International humanitarian groups are also concerned that weakened IPR policies in India would hurt patients in developing countries. &quot;India has earned itself the title of the pharmacy of the world through its inexpensive generic drugs,&quot; said Leena Menghaney, an India representative with Medicins Sans Frontieres that procures drugs against malaria, tuberculosis, and HIV from India for patients in other developing countries.</p><p align="justify">&quot;What we're witnessing now are intense efforts to find ways to weaken or bypass the patent law that was passed by the Indian Parliament - unanimously by members of all political parties,&quot; said Dinesh Abrol, the convener of the National Working Group on Patent Laws.</p>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$reasonPhrase = 'OK'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitStatusLine() - CORE/src/Http/ResponseEmitter.php, line 148
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 54
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 181]
Code Context
                    $value

                ), $first);

                $first = false;
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr6803085150bda-trace').style.display = (document.getElementById('cakeErr6803085150bda-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr6803085150bda-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr6803085150bda-code').style.display = (document.getElementById('cakeErr6803085150bda-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr6803085150bda-context').style.display = (document.getElementById('cakeErr6803085150bda-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr6803085150bda-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr6803085150bda-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 27103,
		&#039;title&#039; =&gt; &#039;Patients&amp;#039; groups voice patent fears&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Telegraph
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;em&gt;New Delhi: &lt;/em&gt;Health and patients&#039; rights groups have called on the government to resist American pressure that they claimed was aimed at weakening safeguards in India&#039;s patent laws that allow drug companies to sell inexpensive generic medicine.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Health activists representing patients&#039; rights said they were concerned that bilateral talks on intellectual property rights, to feature during US President Barack Obama&#039;s visit to India beginning this weekend, may be rigged against access to affordable medicine for patients in India and other countries.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
They said their concerns were based on a series of developments since Prime Minister Narendra Modi&#039;s return from a visit to the US in September 2014 that, they claimed, suggested that the US was accelerating its efforts to weaken or bypass India&#039;s pro-poor patent laws.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
India&#039;s patent laws contain a section titled 3(d) that prohibits patents on minor variations of known drug molecules. Patients&#039; rights groups view this as a safeguard, facilitating the production of generic inexpensive versions of medicines sold in India and many other countries.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Indian patent examiners have denied patents citing 3(d), which sections of foreign pharmaceutical industry see as a hindrance to innovation.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;(Narendra) Modi has portrayed himself as a strong man - we&#039;re calling on Modi to show his strength now and resist pressure from the US,&amp;quot; said Anand Grover, director of Lawyers Collective, a network of lawyers that has represented patients&#039; groups to challenge patent decisions in court.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Grover and others view bilateral mechanisms set up through the US-India Trade Policy Forum and an investigation into Indian patent laws initiated by the US International Trade Commission in October 2014 as signals of the growing US pressure on India to tweak the way it manages patents.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
They said certain actions by the Indian government also suggested that it was willing to rethink India&#039;s patent regime. The government last year established a think-tank on intellectual property rights (IPR) and decided to defer a decision to allow generic production of an anti-cancer drug.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;We welcome President Obama as a representative of the US people, but we don&#039;t want him here as a representative of US pharmaceutical companies,&amp;quot; said Amit Sengupta, a physician who is the convener of Jan Swasthya Abhiyan, or People&#039;s Health Network, a non-government group of health activists.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Grover said the draft national policy on intellectual property released by the government&#039;s new think-tank is &amp;quot;glaringly ignorant and promotes intellectual property as the only solution for innovation and creativity in India, contrary to the evidence&amp;quot;.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
International humanitarian groups are also concerned that weakened IPR policies in India would hurt patients in developing countries. &amp;quot;India has earned itself the title of the pharmacy of the world through its inexpensive generic drugs,&amp;quot; said Leena Menghaney, an India representative with Medicins Sans Frontieres that procures drugs against malaria, tuberculosis, and HIV from India for patients in other developing countries.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;What we&#039;re witnessing now are intense efforts to find ways to weaken or bypass the patent law that was passed by the Indian Parliament - unanimously by members of all political parties,&amp;quot; said Dinesh Abrol, the convener of the National Working Group on Patent Laws.
&lt;/p&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Telegraph, 24 January, 2015, http://www.telegraphindia.com/1150124/jsp/nation/story_9985.jsp#.VMNmUC7xyBE&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;patients039-groups-voice-patent-fears-4675150&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 4675150,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 27103,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Patients&amp;#039; groups voice patent fears&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;Access to Health,Access to Healthcare,Access to Medicines,Intellectual Property Rights,patent,patents,IPRs,medicines&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Telegraph


New Delhi: Health and patients&#039; rights groups have called on the government to resist American pressure that they claimed was aimed at weakening safeguards in India&#039;s patent laws that allow drug companies to sell inexpensive generic medicine.


Health activists representing...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Telegraph&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;em&gt;New Delhi: &lt;/em&gt;Health and patients&#039; rights groups have called on the government to resist American pressure that they claimed was aimed at weakening safeguards in India&#039;s patent laws that allow drug companies to sell inexpensive generic medicine.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Health activists representing patients&#039; rights said they were concerned that bilateral talks on intellectual property rights, to feature during US President Barack Obama&#039;s visit to India beginning this weekend, may be rigged against access to affordable medicine for patients in India and other countries.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;They said their concerns were based on a series of developments since Prime Minister Narendra Modi&#039;s return from a visit to the US in September 2014 that, they claimed, suggested that the US was accelerating its efforts to weaken or bypass India&#039;s pro-poor patent laws.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;India&#039;s patent laws contain a section titled 3(d) that prohibits patents on minor variations of known drug molecules. Patients&#039; rights groups view this as a safeguard, facilitating the production of generic inexpensive versions of medicines sold in India and many other countries.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Indian patent examiners have denied patents citing 3(d), which sections of foreign pharmaceutical industry see as a hindrance to innovation.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;(Narendra) Modi has portrayed himself as a strong man - we&#039;re calling on Modi to show his strength now and resist pressure from the US,&amp;quot; said Anand Grover, director of Lawyers Collective, a network of lawyers that has represented patients&#039; groups to challenge patent decisions in court.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Grover and others view bilateral mechanisms set up through the US-India Trade Policy Forum and an investigation into Indian patent laws initiated by the US International Trade Commission in October 2014 as signals of the growing US pressure on India to tweak the way it manages patents.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;They said certain actions by the Indian government also suggested that it was willing to rethink India&#039;s patent regime. The government last year established a think-tank on intellectual property rights (IPR) and decided to defer a decision to allow generic production of an anti-cancer drug.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;We welcome President Obama as a representative of the US people, but we don&#039;t want him here as a representative of US pharmaceutical companies,&amp;quot; said Amit Sengupta, a physician who is the convener of Jan Swasthya Abhiyan, or People&#039;s Health Network, a non-government group of health activists.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Grover said the draft national policy on intellectual property released by the government&#039;s new think-tank is &amp;quot;glaringly ignorant and promotes intellectual property as the only solution for innovation and creativity in India, contrary to the evidence&amp;quot;.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;International humanitarian groups are also concerned that weakened IPR policies in India would hurt patients in developing countries. &amp;quot;India has earned itself the title of the pharmacy of the world through its inexpensive generic drugs,&amp;quot; said Leena Menghaney, an India representative with Medicins Sans Frontieres that procures drugs against malaria, tuberculosis, and HIV from India for patients in other developing countries.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;What we&#039;re witnessing now are intense efforts to find ways to weaken or bypass the patent law that was passed by the Indian Parliament - unanimously by members of all political parties,&amp;quot; said Dinesh Abrol, the convener of the National Working Group on Patent Laws.&lt;/p&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 27103,
	&#039;title&#039; =&gt; &#039;Patients&amp;#039; groups voice patent fears&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Telegraph
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;em&gt;New Delhi: &lt;/em&gt;Health and patients&#039; rights groups have called on the government to resist American pressure that they claimed was aimed at weakening safeguards in India&#039;s patent laws that allow drug companies to sell inexpensive generic medicine.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Health activists representing patients&#039; rights said they were concerned that bilateral talks on intellectual property rights, to feature during US President Barack Obama&#039;s visit to India beginning this weekend, may be rigged against access to affordable medicine for patients in India and other countries.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
They said their concerns were based on a series of developments since Prime Minister Narendra Modi&#039;s return from a visit to the US in September 2014 that, they claimed, suggested that the US was accelerating its efforts to weaken or bypass India&#039;s pro-poor patent laws.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
India&#039;s patent laws contain a section titled 3(d) that prohibits patents on minor variations of known drug molecules. Patients&#039; rights groups view this as a safeguard, facilitating the production of generic inexpensive versions of medicines sold in India and many other countries.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Indian patent examiners have denied patents citing 3(d), which sections of foreign pharmaceutical industry see as a hindrance to innovation.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;(Narendra) Modi has portrayed himself as a strong man - we&#039;re calling on Modi to show his strength now and resist pressure from the US,&amp;quot; said Anand Grover, director of Lawyers Collective, a network of lawyers that has represented patients&#039; groups to challenge patent decisions in court.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Grover and others view bilateral mechanisms set up through the US-India Trade Policy Forum and an investigation into Indian patent laws initiated by the US International Trade Commission in October 2014 as signals of the growing US pressure on India to tweak the way it manages patents.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
They said certain actions by the Indian government also suggested that it was willing to rethink India&#039;s patent regime. The government last year established a think-tank on intellectual property rights (IPR) and decided to defer a decision to allow generic production of an anti-cancer drug.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;We welcome President Obama as a representative of the US people, but we don&#039;t want him here as a representative of US pharmaceutical companies,&amp;quot; said Amit Sengupta, a physician who is the convener of Jan Swasthya Abhiyan, or People&#039;s Health Network, a non-government group of health activists.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Grover said the draft national policy on intellectual property released by the government&#039;s new think-tank is &amp;quot;glaringly ignorant and promotes intellectual property as the only solution for innovation and creativity in India, contrary to the evidence&amp;quot;.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
International humanitarian groups are also concerned that weakened IPR policies in India would hurt patients in developing countries. &amp;quot;India has earned itself the title of the pharmacy of the world through its inexpensive generic drugs,&amp;quot; said Leena Menghaney, an India representative with Medicins Sans Frontieres that procures drugs against malaria, tuberculosis, and HIV from India for patients in other developing countries.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;What we&#039;re witnessing now are intense efforts to find ways to weaken or bypass the patent law that was passed by the Indian Parliament - unanimously by members of all political parties,&amp;quot; said Dinesh Abrol, the convener of the National Working Group on Patent Laws.
&lt;/p&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Telegraph, 24 January, 2015, http://www.telegraphindia.com/1150124/jsp/nation/story_9985.jsp#.VMNmUC7xyBE&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;patients039-groups-voice-patent-fears-4675150&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 4675150,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {},
		(int) 3 =&gt; object(Cake\ORM\Entity) {},
		(int) 4 =&gt; object(Cake\ORM\Entity) {},
		(int) 5 =&gt; object(Cake\ORM\Entity) {},
		(int) 6 =&gt; object(Cake\ORM\Entity) {},
		(int) 7 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 27103
$metaTitle = &#039;LATEST NEWS UPDATES | Patients&amp;#039; groups voice patent fears&#039;
$metaKeywords = &#039;Access to Health,Access to Healthcare,Access to Medicines,Intellectual Property Rights,patent,patents,IPRs,medicines&#039;
$metaDesc = &#039;
-The Telegraph


New Delhi: Health and patients&#039; rights groups have called on the government to resist American pressure that they claimed was aimed at weakening safeguards in India&#039;s patent laws that allow drug companies to sell inexpensive generic medicine.


Health activists representing...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Telegraph&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;em&gt;New Delhi: &lt;/em&gt;Health and patients&#039; rights groups have called on the government to resist American pressure that they claimed was aimed at weakening safeguards in India&#039;s patent laws that allow drug companies to sell inexpensive generic medicine.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Health activists representing patients&#039; rights said they were concerned that bilateral talks on intellectual property rights, to feature during US President Barack Obama&#039;s visit to India beginning this weekend, may be rigged against access to affordable medicine for patients in India and other countries.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;They said their concerns were based on a series of developments since Prime Minister Narendra Modi&#039;s return from a visit to the US in September 2014 that, they claimed, suggested that the US was accelerating its efforts to weaken or bypass India&#039;s pro-poor patent laws.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;India&#039;s patent laws contain a section titled 3(d) that prohibits patents on minor variations of known drug molecules. Patients&#039; rights groups view this as a safeguard, facilitating the production of generic inexpensive versions of medicines sold in India and many other countries.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Indian patent examiners have denied patents citing 3(d), which sections of foreign pharmaceutical industry see as a hindrance to innovation.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;(Narendra) Modi has portrayed himself as a strong man - we&#039;re calling on Modi to show his strength now and resist pressure from the US,&amp;quot; said Anand Grover, director of Lawyers Collective, a network of lawyers that has represented patients&#039; groups to challenge patent decisions in court.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Grover and others view bilateral mechanisms set up through the US-India Trade Policy Forum and an investigation into Indian patent laws initiated by the US International Trade Commission in October 2014 as signals of the growing US pressure on India to tweak the way it manages patents.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;They said certain actions by the Indian government also suggested that it was willing to rethink India&#039;s patent regime. The government last year established a think-tank on intellectual property rights (IPR) and decided to defer a decision to allow generic production of an anti-cancer drug.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;We welcome President Obama as a representative of the US people, but we don&#039;t want him here as a representative of US pharmaceutical companies,&amp;quot; said Amit Sengupta, a physician who is the convener of Jan Swasthya Abhiyan, or People&#039;s Health Network, a non-government group of health activists.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Grover said the draft national policy on intellectual property released by the government&#039;s new think-tank is &amp;quot;glaringly ignorant and promotes intellectual property as the only solution for innovation and creativity in India, contrary to the evidence&amp;quot;.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;International humanitarian groups are also concerned that weakened IPR policies in India would hurt patients in developing countries. &amp;quot;India has earned itself the title of the pharmacy of the world through its inexpensive generic drugs,&amp;quot; said Leena Menghaney, an India representative with Medicins Sans Frontieres that procures drugs against malaria, tuberculosis, and HIV from India for patients in other developing countries.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;What we&#039;re witnessing now are intense efforts to find ways to weaken or bypass the patent law that was passed by the Indian Parliament - unanimously by members of all political parties,&amp;quot; said Dinesh Abrol, the convener of the National Working Group on Patent Laws.&lt;/p&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/patients039-groups-voice-patent-fears-4675150.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Patients&#039; groups voice patent fears | Im4change.org</title>
    <meta name="description" content="
-The Telegraph


New Delhi: Health and patients' rights groups have called on the government to resist American pressure that they claimed was aimed at weakening safeguards in India's patent laws that allow drug companies to sell inexpensive generic medicine.


Health activists representing..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Patients&#039; groups voice patent fears</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Telegraph</div><p align="justify"><em>New Delhi: </em>Health and patients' rights groups have called on the government to resist American pressure that they claimed was aimed at weakening safeguards in India's patent laws that allow drug companies to sell inexpensive generic medicine.</p><p align="justify">Health activists representing patients' rights said they were concerned that bilateral talks on intellectual property rights, to feature during US President Barack Obama's visit to India beginning this weekend, may be rigged against access to affordable medicine for patients in India and other countries.</p><p align="justify">They said their concerns were based on a series of developments since Prime Minister Narendra Modi's return from a visit to the US in September 2014 that, they claimed, suggested that the US was accelerating its efforts to weaken or bypass India's pro-poor patent laws.</p><p align="justify">India's patent laws contain a section titled 3(d) that prohibits patents on minor variations of known drug molecules. Patients' rights groups view this as a safeguard, facilitating the production of generic inexpensive versions of medicines sold in India and many other countries.</p><p align="justify">Indian patent examiners have denied patents citing 3(d), which sections of foreign pharmaceutical industry see as a hindrance to innovation.</p><p align="justify">&quot;(Narendra) Modi has portrayed himself as a strong man - we're calling on Modi to show his strength now and resist pressure from the US,&quot; said Anand Grover, director of Lawyers Collective, a network of lawyers that has represented patients' groups to challenge patent decisions in court.</p><p align="justify">Grover and others view bilateral mechanisms set up through the US-India Trade Policy Forum and an investigation into Indian patent laws initiated by the US International Trade Commission in October 2014 as signals of the growing US pressure on India to tweak the way it manages patents.</p><p align="justify">They said certain actions by the Indian government also suggested that it was willing to rethink India's patent regime. The government last year established a think-tank on intellectual property rights (IPR) and decided to defer a decision to allow generic production of an anti-cancer drug.</p><p align="justify">&quot;We welcome President Obama as a representative of the US people, but we don't want him here as a representative of US pharmaceutical companies,&quot; said Amit Sengupta, a physician who is the convener of Jan Swasthya Abhiyan, or People's Health Network, a non-government group of health activists.</p><p align="justify">Grover said the draft national policy on intellectual property released by the government's new think-tank is &quot;glaringly ignorant and promotes intellectual property as the only solution for innovation and creativity in India, contrary to the evidence&quot;.</p><p align="justify">International humanitarian groups are also concerned that weakened IPR policies in India would hurt patients in developing countries. &quot;India has earned itself the title of the pharmacy of the world through its inexpensive generic drugs,&quot; said Leena Menghaney, an India representative with Medicins Sans Frontieres that procures drugs against malaria, tuberculosis, and HIV from India for patients in other developing countries.</p><p align="justify">&quot;What we're witnessing now are intense efforts to find ways to weaken or bypass the patent law that was passed by the Indian Parliament - unanimously by members of all political parties,&quot; said Dinesh Abrol, the convener of the National Working Group on Patent Laws.</p>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$cookies = []
$values = [
	(int) 0 => 'text/html; charset=UTF-8'
]
$name = 'Content-Type'
$first = true
$value = 'text/html; charset=UTF-8'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitHeaders() - CORE/src/Http/ResponseEmitter.php, line 181
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 55
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

<head>

    <link rel="canonical" href="<?php echo Configure::read('SITE_URL'); ?><?php echo $urlPrefix;?><?php echo $article_current->category->slug; ?>/<?php echo $article_current->seo_url; ?>.html"/>

    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>

$viewFile = '/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp'
$dataForView = [
	'article_current' => object(App\Model\Entity\Article) {

		'id' => (int) 27103,
		'title' => 'Patients' groups voice patent fears',
		'subheading' => '',
		'description' => '<div align="justify">
-The Telegraph
</div>
<p align="justify">
<em>New Delhi: </em>Health and patients' rights groups have called on the government to resist American pressure that they claimed was aimed at weakening safeguards in India's patent laws that allow drug companies to sell inexpensive generic medicine.
</p>
<p align="justify">
Health activists representing patients' rights said they were concerned that bilateral talks on intellectual property rights, to feature during US President Barack Obama's visit to India beginning this weekend, may be rigged against access to affordable medicine for patients in India and other countries.
</p>
<p align="justify">
They said their concerns were based on a series of developments since Prime Minister Narendra Modi's return from a visit to the US in September 2014 that, they claimed, suggested that the US was accelerating its efforts to weaken or bypass India's pro-poor patent laws.
</p>
<p align="justify">
India's patent laws contain a section titled 3(d) that prohibits patents on minor variations of known drug molecules. Patients' rights groups view this as a safeguard, facilitating the production of generic inexpensive versions of medicines sold in India and many other countries.
</p>
<p align="justify">
Indian patent examiners have denied patents citing 3(d), which sections of foreign pharmaceutical industry see as a hindrance to innovation.
</p>
<p align="justify">
&quot;(Narendra) Modi has portrayed himself as a strong man - we're calling on Modi to show his strength now and resist pressure from the US,&quot; said Anand Grover, director of Lawyers Collective, a network of lawyers that has represented patients' groups to challenge patent decisions in court.
</p>
<p align="justify">
Grover and others view bilateral mechanisms set up through the US-India Trade Policy Forum and an investigation into Indian patent laws initiated by the US International Trade Commission in October 2014 as signals of the growing US pressure on India to tweak the way it manages patents.
</p>
<p align="justify">
They said certain actions by the Indian government also suggested that it was willing to rethink India's patent regime. The government last year established a think-tank on intellectual property rights (IPR) and decided to defer a decision to allow generic production of an anti-cancer drug.
</p>
<p align="justify">
&quot;We welcome President Obama as a representative of the US people, but we don't want him here as a representative of US pharmaceutical companies,&quot; said Amit Sengupta, a physician who is the convener of Jan Swasthya Abhiyan, or People's Health Network, a non-government group of health activists.
</p>
<p align="justify">
Grover said the draft national policy on intellectual property released by the government's new think-tank is &quot;glaringly ignorant and promotes intellectual property as the only solution for innovation and creativity in India, contrary to the evidence&quot;.
</p>
<p align="justify">
International humanitarian groups are also concerned that weakened IPR policies in India would hurt patients in developing countries. &quot;India has earned itself the title of the pharmacy of the world through its inexpensive generic drugs,&quot; said Leena Menghaney, an India representative with Medicins Sans Frontieres that procures drugs against malaria, tuberculosis, and HIV from India for patients in other developing countries.
</p>
<p align="justify">
&quot;What we're witnessing now are intense efforts to find ways to weaken or bypass the patent law that was passed by the Indian Parliament - unanimously by members of all political parties,&quot; said Dinesh Abrol, the convener of the National Working Group on Patent Laws.
</p>',
		'credit_writer' => 'The Telegraph, 24 January, 2015, http://www.telegraphindia.com/1150124/jsp/nation/story_9985.jsp#.VMNmUC7xyBE',
		'article_img' => '',
		'article_img_thumb' => '',
		'status' => (int) 1,
		'show_on_home' => (int) 1,
		'lang' => 'EN',
		'category_id' => (int) 16,
		'tag_keyword' => '',
		'seo_url' => 'patients039-groups-voice-patent-fears-4675150',
		'meta_title' => null,
		'meta_keywords' => null,
		'meta_description' => null,
		'noindex' => (int) 0,
		'publish_date' => object(Cake\I18n\FrozenDate) {},
		'most_visit_section_id' => null,
		'article_big_img' => null,
		'liveid' => (int) 4675150,
		'created' => object(Cake\I18n\FrozenTime) {},
		'modified' => object(Cake\I18n\FrozenTime) {},
		'edate' => '',
		'tags' => [
			[maximum depth reached]
		],
		'category' => object(App\Model\Entity\Category) {},
		'[new]' => false,
		'[accessible]' => [
			[maximum depth reached]
		],
		'[dirty]' => [[maximum depth reached]],
		'[original]' => [[maximum depth reached]],
		'[virtual]' => [[maximum depth reached]],
		'[hasErrors]' => false,
		'[errors]' => [[maximum depth reached]],
		'[invalid]' => [[maximum depth reached]],
		'[repository]' => 'Articles'
	
	},
	'articleid' => (int) 27103,
	'metaTitle' => 'LATEST NEWS UPDATES | Patients&#039; groups voice patent fears',
	'metaKeywords' => 'Access to Health,Access to Healthcare,Access to Medicines,Intellectual Property Rights,patent,patents,IPRs,medicines',
	'metaDesc' => '
-The Telegraph


New Delhi: Health and patients' rights groups have called on the government to resist American pressure that they claimed was aimed at weakening safeguards in India's patent laws that allow drug companies to sell inexpensive generic medicine.


Health activists representing...',
	'disp' => '<div align="justify">-The Telegraph</div><p align="justify"><em>New Delhi: </em>Health and patients' rights groups have called on the government to resist American pressure that they claimed was aimed at weakening safeguards in India's patent laws that allow drug companies to sell inexpensive generic medicine.</p><p align="justify">Health activists representing patients' rights said they were concerned that bilateral talks on intellectual property rights, to feature during US President Barack Obama's visit to India beginning this weekend, may be rigged against access to affordable medicine for patients in India and other countries.</p><p align="justify">They said their concerns were based on a series of developments since Prime Minister Narendra Modi's return from a visit to the US in September 2014 that, they claimed, suggested that the US was accelerating its efforts to weaken or bypass India's pro-poor patent laws.</p><p align="justify">India's patent laws contain a section titled 3(d) that prohibits patents on minor variations of known drug molecules. Patients' rights groups view this as a safeguard, facilitating the production of generic inexpensive versions of medicines sold in India and many other countries.</p><p align="justify">Indian patent examiners have denied patents citing 3(d), which sections of foreign pharmaceutical industry see as a hindrance to innovation.</p><p align="justify">&quot;(Narendra) Modi has portrayed himself as a strong man - we're calling on Modi to show his strength now and resist pressure from the US,&quot; said Anand Grover, director of Lawyers Collective, a network of lawyers that has represented patients' groups to challenge patent decisions in court.</p><p align="justify">Grover and others view bilateral mechanisms set up through the US-India Trade Policy Forum and an investigation into Indian patent laws initiated by the US International Trade Commission in October 2014 as signals of the growing US pressure on India to tweak the way it manages patents.</p><p align="justify">They said certain actions by the Indian government also suggested that it was willing to rethink India's patent regime. The government last year established a think-tank on intellectual property rights (IPR) and decided to defer a decision to allow generic production of an anti-cancer drug.</p><p align="justify">&quot;We welcome President Obama as a representative of the US people, but we don't want him here as a representative of US pharmaceutical companies,&quot; said Amit Sengupta, a physician who is the convener of Jan Swasthya Abhiyan, or People's Health Network, a non-government group of health activists.</p><p align="justify">Grover said the draft national policy on intellectual property released by the government's new think-tank is &quot;glaringly ignorant and promotes intellectual property as the only solution for innovation and creativity in India, contrary to the evidence&quot;.</p><p align="justify">International humanitarian groups are also concerned that weakened IPR policies in India would hurt patients in developing countries. &quot;India has earned itself the title of the pharmacy of the world through its inexpensive generic drugs,&quot; said Leena Menghaney, an India representative with Medicins Sans Frontieres that procures drugs against malaria, tuberculosis, and HIV from India for patients in other developing countries.</p><p align="justify">&quot;What we're witnessing now are intense efforts to find ways to weaken or bypass the patent law that was passed by the Indian Parliament - unanimously by members of all political parties,&quot; said Dinesh Abrol, the convener of the National Working Group on Patent Laws.</p>',
	'lang' => 'English',
	'SITE_URL' => 'https://im4change.in/',
	'site_title' => 'im4change',
	'adminprix' => 'admin'
]
$article_current = object(App\Model\Entity\Article) {

	'id' => (int) 27103,
	'title' => 'Patients&#039; groups voice patent fears',
	'subheading' => '',
	'description' => '<div align="justify">
-The Telegraph
</div>
<p align="justify">
<em>New Delhi: </em>Health and patients' rights groups have called on the government to resist American pressure that they claimed was aimed at weakening safeguards in India's patent laws that allow drug companies to sell inexpensive generic medicine.
</p>
<p align="justify">
Health activists representing patients' rights said they were concerned that bilateral talks on intellectual property rights, to feature during US President Barack Obama's visit to India beginning this weekend, may be rigged against access to affordable medicine for patients in India and other countries.
</p>
<p align="justify">
They said their concerns were based on a series of developments since Prime Minister Narendra Modi's return from a visit to the US in September 2014 that, they claimed, suggested that the US was accelerating its efforts to weaken or bypass India's pro-poor patent laws.
</p>
<p align="justify">
India's patent laws contain a section titled 3(d) that prohibits patents on minor variations of known drug molecules. Patients' rights groups view this as a safeguard, facilitating the production of generic inexpensive versions of medicines sold in India and many other countries.
</p>
<p align="justify">
Indian patent examiners have denied patents citing 3(d), which sections of foreign pharmaceutical industry see as a hindrance to innovation.
</p>
<p align="justify">
&quot;(Narendra) Modi has portrayed himself as a strong man - we're calling on Modi to show his strength now and resist pressure from the US,&quot; said Anand Grover, director of Lawyers Collective, a network of lawyers that has represented patients' groups to challenge patent decisions in court.
</p>
<p align="justify">
Grover and others view bilateral mechanisms set up through the US-India Trade Policy Forum and an investigation into Indian patent laws initiated by the US International Trade Commission in October 2014 as signals of the growing US pressure on India to tweak the way it manages patents.
</p>
<p align="justify">
They said certain actions by the Indian government also suggested that it was willing to rethink India's patent regime. The government last year established a think-tank on intellectual property rights (IPR) and decided to defer a decision to allow generic production of an anti-cancer drug.
</p>
<p align="justify">
&quot;We welcome President Obama as a representative of the US people, but we don't want him here as a representative of US pharmaceutical companies,&quot; said Amit Sengupta, a physician who is the convener of Jan Swasthya Abhiyan, or People's Health Network, a non-government group of health activists.
</p>
<p align="justify">
Grover said the draft national policy on intellectual property released by the government's new think-tank is &quot;glaringly ignorant and promotes intellectual property as the only solution for innovation and creativity in India, contrary to the evidence&quot;.
</p>
<p align="justify">
International humanitarian groups are also concerned that weakened IPR policies in India would hurt patients in developing countries. &quot;India has earned itself the title of the pharmacy of the world through its inexpensive generic drugs,&quot; said Leena Menghaney, an India representative with Medicins Sans Frontieres that procures drugs against malaria, tuberculosis, and HIV from India for patients in other developing countries.
</p>
<p align="justify">
&quot;What we're witnessing now are intense efforts to find ways to weaken or bypass the patent law that was passed by the Indian Parliament - unanimously by members of all political parties,&quot; said Dinesh Abrol, the convener of the National Working Group on Patent Laws.
</p>',
	'credit_writer' => 'The Telegraph, 24 January, 2015, http://www.telegraphindia.com/1150124/jsp/nation/story_9985.jsp#.VMNmUC7xyBE',
	'article_img' => '',
	'article_img_thumb' => '',
	'status' => (int) 1,
	'show_on_home' => (int) 1,
	'lang' => 'EN',
	'category_id' => (int) 16,
	'tag_keyword' => '',
	'seo_url' => 'patients039-groups-voice-patent-fears-4675150',
	'meta_title' => null,
	'meta_keywords' => null,
	'meta_description' => null,
	'noindex' => (int) 0,
	'publish_date' => object(Cake\I18n\FrozenDate) {},
	'most_visit_section_id' => null,
	'article_big_img' => null,
	'liveid' => (int) 4675150,
	'created' => object(Cake\I18n\FrozenTime) {},
	'modified' => object(Cake\I18n\FrozenTime) {},
	'edate' => '',
	'tags' => [
		(int) 0 => object(Cake\ORM\Entity) {},
		(int) 1 => object(Cake\ORM\Entity) {},
		(int) 2 => object(Cake\ORM\Entity) {},
		(int) 3 => object(Cake\ORM\Entity) {},
		(int) 4 => object(Cake\ORM\Entity) {},
		(int) 5 => object(Cake\ORM\Entity) {},
		(int) 6 => object(Cake\ORM\Entity) {},
		(int) 7 => object(Cake\ORM\Entity) {}
	],
	'category' => object(App\Model\Entity\Category) {},
	'[new]' => false,
	'[accessible]' => [
		'*' => true,
		'id' => false
	],
	'[dirty]' => [],
	'[original]' => [],
	'[virtual]' => [],
	'[hasErrors]' => false,
	'[errors]' => [],
	'[invalid]' => [],
	'[repository]' => 'Articles'

}
$articleid = (int) 27103
$metaTitle = 'LATEST NEWS UPDATES | Patients&#039; groups voice patent fears'
$metaKeywords = 'Access to Health,Access to Healthcare,Access to Medicines,Intellectual Property Rights,patent,patents,IPRs,medicines'
$metaDesc = '
-The Telegraph


New Delhi: Health and patients' rights groups have called on the government to resist American pressure that they claimed was aimed at weakening safeguards in India's patent laws that allow drug companies to sell inexpensive generic medicine.


Health activists representing...'
$disp = '<div align="justify">-The Telegraph</div><p align="justify"><em>New Delhi: </em>Health and patients' rights groups have called on the government to resist American pressure that they claimed was aimed at weakening safeguards in India's patent laws that allow drug companies to sell inexpensive generic medicine.</p><p align="justify">Health activists representing patients' rights said they were concerned that bilateral talks on intellectual property rights, to feature during US President Barack Obama's visit to India beginning this weekend, may be rigged against access to affordable medicine for patients in India and other countries.</p><p align="justify">They said their concerns were based on a series of developments since Prime Minister Narendra Modi's return from a visit to the US in September 2014 that, they claimed, suggested that the US was accelerating its efforts to weaken or bypass India's pro-poor patent laws.</p><p align="justify">India's patent laws contain a section titled 3(d) that prohibits patents on minor variations of known drug molecules. Patients' rights groups view this as a safeguard, facilitating the production of generic inexpensive versions of medicines sold in India and many other countries.</p><p align="justify">Indian patent examiners have denied patents citing 3(d), which sections of foreign pharmaceutical industry see as a hindrance to innovation.</p><p align="justify">&quot;(Narendra) Modi has portrayed himself as a strong man - we're calling on Modi to show his strength now and resist pressure from the US,&quot; said Anand Grover, director of Lawyers Collective, a network of lawyers that has represented patients' groups to challenge patent decisions in court.</p><p align="justify">Grover and others view bilateral mechanisms set up through the US-India Trade Policy Forum and an investigation into Indian patent laws initiated by the US International Trade Commission in October 2014 as signals of the growing US pressure on India to tweak the way it manages patents.</p><p align="justify">They said certain actions by the Indian government also suggested that it was willing to rethink India's patent regime. The government last year established a think-tank on intellectual property rights (IPR) and decided to defer a decision to allow generic production of an anti-cancer drug.</p><p align="justify">&quot;We welcome President Obama as a representative of the US people, but we don't want him here as a representative of US pharmaceutical companies,&quot; said Amit Sengupta, a physician who is the convener of Jan Swasthya Abhiyan, or People's Health Network, a non-government group of health activists.</p><p align="justify">Grover said the draft national policy on intellectual property released by the government's new think-tank is &quot;glaringly ignorant and promotes intellectual property as the only solution for innovation and creativity in India, contrary to the evidence&quot;.</p><p align="justify">International humanitarian groups are also concerned that weakened IPR policies in India would hurt patients in developing countries. &quot;India has earned itself the title of the pharmacy of the world through its inexpensive generic drugs,&quot; said Leena Menghaney, an India representative with Medicins Sans Frontieres that procures drugs against malaria, tuberculosis, and HIV from India for patients in other developing countries.</p><p align="justify">&quot;What we're witnessing now are intense efforts to find ways to weaken or bypass the patent law that was passed by the Indian Parliament - unanimously by members of all political parties,&quot; said Dinesh Abrol, the convener of the National Working Group on Patent Laws.</p>'
$lang = 'English'
$SITE_URL = 'https://im4change.in/'
$site_title = 'im4change'
$adminprix = 'admin'

include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51

Patients' groups voice patent fears

-The Telegraph New Delhi: Health and patients' rights groups have called on the government to resist American pressure that they claimed was aimed at weakening safeguards in India's patent laws that allow drug companies to sell inexpensive generic medicine. Health activists representing patients' rights said they were concerned that bilateral talks on intellectual property rights, to feature during US President Barack Obama's visit to India beginning this weekend, may be rigged against access to affordable medicine for patients in India and other countries. They said their concerns were based on a series of developments since Prime Minister Narendra Modi's return from a visit to the US in September 2014 that, they claimed, suggested that the US was accelerating its efforts to weaken or bypass India's pro-poor patent laws. India's patent laws contain a section titled 3(d) that prohibits patents on minor variations of known drug molecules. Patients' rights groups view this as a safeguard, facilitating the production of generic inexpensive versions of medicines sold in India and many other countries. Indian patent examiners have denied patents citing 3(d), which sections of foreign pharmaceutical industry see as a hindrance to innovation. "(Narendra) Modi has portrayed himself as a strong man - we're calling on Modi to show his strength now and resist pressure from the US," said Anand Grover, director of Lawyers Collective, a network of lawyers that has represented patients' groups to challenge patent decisions in court. Grover and others view bilateral mechanisms set up through the US-India Trade Policy Forum and an investigation into Indian patent laws initiated by the US International Trade Commission in October 2014 as signals of the growing US pressure on India to tweak the way it manages patents. They said certain actions by the Indian government also suggested that it was willing to rethink India's patent regime. The government last year established a think-tank on intellectual property rights (IPR) and decided to defer a decision to allow generic production of an anti-cancer drug. "We welcome President Obama as a representative of the US people, but we don't want him here as a representative of US pharmaceutical companies," said Amit Sengupta, a physician who is the convener of Jan Swasthya Abhiyan, or People's Health Network, a non-government group of health activists. Grover said the draft national policy on intellectual property released by the government's new think-tank is "glaringly ignorant and promotes intellectual property as the only solution for innovation and creativity in India, contrary to the evidence". International humanitarian groups are also concerned that weakened IPR policies in India would hurt patients in developing countries. "India has earned itself the title of the pharmacy of the world through its inexpensive generic drugs," said Leena Menghaney, an India representative with Medicins Sans Frontieres that procures drugs against malaria, tuberculosis, and HIV from India for patients in other developing countries. "What we're witnessing now are intense efforts to find ways to weaken or bypass the patent law that was passed by the Indian Parliament - unanimously by members of all political parties," said Dinesh Abrol, the convener of the National Working Group on Patent Laws.